21 June 2018 / Posted in: Help Us
We would like to say a huge Thank You to everyone who has supported the very first Marathon in May for SMA.
21 June 2018 / Posted in: Research
PTC Therapeutics recently presented preliminary data from the FIREFISH Phase II clinical trial of their splice-modifying drug, RG7916, at the 2018 Cure SMA conference in Dallas, USA.
20 June 2018 / Posted in: Research
Cytokinetics presented data at the 2018 Cure SMA conference from the Phase II clinical trial with SMA patients of its drug CK-2127107, which has been renamed reldesemtiv.
19 June 2018 / Posted in: Research
A statement came out yesterday that explains how patients with rare diseases in Scotland could get faster access to new treatments following a revised decision-making process. The Scottish Government is introducing a new definition of 'ultra-orphan medicines' that can treat rare conditions.
19 June 2018 / Posted in: Help Us
Find out more about exciting events that are happening in Scotland over the summer which you could take part in to help raise money for SMA Support UK.
18 June 2018 / Posted in: Research
We have asked Biogen to keep us updated with this latest information as we all continue to advocate for broad access in the UK.
14 June 2018 / Posted in: Information & Support
Carers UK have information on their website and a free, downloadable guide on your right to request flexible working.
14 June 2018 / Posted in: Research
We have received the following update from Roche about the SUNFISH study, investigating RG7916 in people with SMA Types 2 or 3, which will now not be recruiting in the UK.
12 June 2018 / Posted in: Information & Support
After surveying nearly 4,000 adults of all ages who need care or who look after someone with care needs, the Care and Support Alliance (CSA) discovered that people are unable to get the basic care and support they need. Add your voice to their campaign and sign the petition.
08 June 2018 / Posted in: Research
Pharmaceutical company Scholar Rock has announced that dosing of the first cohort has been completed in a Phase I trial of the experimental drug, SRK-015.